A targeted Fe-based MR contrast agent for glioma imaging

Motivation: Neurological adverse effects caused by the deposition of gadolinium-based contrast agents in the brain remain uncertain, and it is necessary to develop a biocompatible alternative molecule for evaluation of glioma malignancy and site occupancy. Goal(s): To demonstrate that Fe-based contrast agents have superior safety, stability, and longevity in glioma imaging compared to gadolinium-based contrast agents. Approach: The T7-Fe-PyC3A was synthesized, and its stability was validated through in vitro kinetic thermodynamic experiments. Furthermore, A in situ glioma model mice was choosen for investigating the imaging ability. Results: A targeted Fe-based MR contrast agent provides clear glioma contours with a 15-60 minutes post-dose imaging window. Impact: Although gadolinium-based contrast agents are widely used in the clinic, iron-based contrast agents targeting gliomas show the enhanced safety and stability profile. The extended imaging window allows them as preferable alternative for gliomas imaging.